Physician profile
Thomas K Ison
NPI 1548290042
$849.42
in general payments reported to CMS, 2019-2025
15 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2021: $116 · 2022: $41.04 · 2023: $81.15 · 2024: $221 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $570.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $193.98 | 2019-2025 | Argos, Rocklatan, Verion |
| Harrow Eye, LLC | $132.10 | 2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $130.68 | 2023-2025 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $103.84 | 2019-2025 | Tecnis Iol |
| Aerie Pharmaceuticals, INC. | $75.06 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $32.70 | 2021-2022 | |
| Horizon Therapeutics Plc | $25.72 | 2021 | |
| Merz Pharmaceuticals, LLC | $24.45 | 2025 | Xeomin |
| Ambu INC. | $23.43 | 2023 | |
| Inspire Medical Systems, INC. | $22.56 | 2023 | Inspire |
| Genmab U.S., INC. | $22.40 | 2024 | Tivdak |
| Amgen INC. | $17.06 | 2025 | Uplizna |
| Sun Pharmaceutical Industries INC. | $16.48 | 2024 | |
| Rxsight INC | $15.41 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Dompe US, INC. | $13.55 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.